Coherus Biosciences | CHRS - Vertriebs- Und Verwaltungskosten





Vertriebs- Und Verwaltungskosten Veränderung Datum
AbbVie USD 3.63B 54M 2026-06
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
Akebia Therapeutics USD 23.53M 3.19M 2025-12
ALKERMES USD 196.64M 67.96M 2026-06
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Amarin USD 18.97M 1.03M 2025-12
Amgen USD 1.72B 134M 2026-06
Baxter International USD 735M 7M 2026-06
Biogen USD 709.7M 155.4M 2026-06
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Coherus Biosciences USD 15M 6.26M 2025-12
Eli Lilly USD 3.43B 496M 2026-06
Fujifilm JPY 236.14B 20.3B 2026-03
Gilead Sciences USD 1.52B 70M 2026-06
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
Merck USD 2.89B 219M 2026-06
Myriad Genetics USD 122.3M 6.7M 2025-12
Pacira USD 91.81M 7.93M 2026-06
Perrigo USD 3.28B 3.02B 2026-06
Pfizer USD 3.41B 496M 2026-06
PTC Therapeutics USD 80.63M 6.74M 2026-06
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
Teva Pharmaceutical Industries USD 1.03B 34M 2026-06
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06
Xencor USD 77.54M 4.59M 2026-06
Zoetis USD 592M 4M 2026-06